Myriad Genetics, Inc. (MYGN)
| Market Cap | 2.30B |
| Revenue (ttm) | 597.50M |
| Net Income (ttm) | -194.10M |
| Shares Out | 74.70M |
| EPS (ttm) | -3.08 |
| PE Ratio | n/a |
| Forward PE | 625.00 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 1 |
| Last Price | $30.95 |
| Previous Close | $30.49 |
| Change ($) | 0.46 |
| Change (%) | 1.51% |
| Day's Open | 31.15 |
| Day's Range | 30.21 - 31.30 |
| Day's Volume | 97,013 |
| 52-Week Range | 9.24 - 31.60 |
Myriad Genetics' (MYGN) sales in majority of the operating segments improved in the quarter despite pandemic-led business challenges.
Myriad (MYGN) delivered earnings and revenue surprises of 0.00% and 4.08%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Myriad Genetics (NASDAQ:MYGN) were unchanged in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 152.17% over the past year ...
New talent and promotions span core businesses, transformation, IT, revenue cycle management, business development, marketing, legal New talent and promotions span core businesses, transformat...
SALT LAKE CITY, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that it will hold its quarterly earnings c...
Myriad Genetics' (MYGN) new study combines a Prolaris molecular risk score approach with a clinical model for predicting a patient's benefit from androgen deprivation therapy.
Results from second study cite Prolaris® as most clinically significant prognostic parameter of outcomes at time of diagnosis, identifying men who need aggressive hormonal treatment and those ...
SALT LAKE CITY, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it will participate at multiple...
Myriad Genetics' (MYGN) GeneSight Psychotropic test is better for predicting patient outcomes and medication blood levels than single-gene testing, per new study.
New Analysis Published in Psychiatry Research
SALT LAKE CITY, Feb. 02, 2021 (GLOBE NEWSWIRE) -- To help more patients with rheumatoid arthritis (RA), Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine...
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Patients with Prostate or Pancreatic Cancer to Benefit from Treatment with Lynparza
NEW YORK, Jan. 18, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiducia...
Myriad Genetics (MYGN) partners with Illumina to expand the access as well as extend the reach of myChoice CDx through its services offering in the international market.
Note: Paul Diaz, President & CEO of Myriad Genetics will speak today at the 39th Annual JP Morgan Healthcare Conference at 2:50 p.m. EST accessible via a live audio webcast at the following di...
SALT LAKE CITY, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it received its first reimburse...
These are the stocks posting the largest moves after hours on Tuesday.
Focus on Women's Health, Oncology, Mental Health to Improve Execution and Accelerate Growth Focus on Women's Health, Oncology, Mental Health to Improve Execution and Accelerate Growth
SALT LAKE CITY, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in precision medicine and molecular diagnostics, will discus...
SALT LAKE CITY, Dec. 11, 2020 (GLOBE NEWSWIRE) -- In a spotlight poster discussion at the 2020 San Antonio Breast Cancer Symposium (SABCS), Myriad Genetics (NASDAQ: MYGN), a global leader in m...
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?
Myriad Genetics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating The post IBD Rating Upgrades: Myriad Genetics Flashes Improved Technical Strength appeare...
FRESNO, Calif., Nov. 30, 2020 /PRNewswire/ -- Integrated Prescription Management (IPM), a leading pharmacy benefits management (PBM) company, has signed a contract with Myriad Genetics, Inc. (...
New nationwide poll shows 1 in 3 respondents age 65+ think they can just “snap out of it” New nationwide poll shows 1 in 3 respondents age 65+ think they can just “snap out of it”
SALT LAKE CITY, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced today the expansion of Myriad...
SALT LAKE CITY, Nov. 11, 2020 (GLOBE NEWSWIRE) -- At the annual meeting of the American College of Rheumatology (ACR), Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics a...
Myriad Genetics' (MYGN) sales in majority of the operating segments plummeted in the quarter owing to the pandemic-led business challenges.
Myriad Genetics' (MYGN) CEO Paul Diaz on Q1 2021 Results - Earnings Call Transcript
Myriad (MYGN) delivered earnings and revenue surprises of 54.55% and 7.86%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
SALT LAKE CITY, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it will hold its quarterly earn...
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
SALT LAKE CITY, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced today that the company has fi...
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?
Rashmi Kumar Elected to Myriad’s Board of Directors Rashmi Kumar Elected to Myriad’s Board of Directors
Let us delve deeper to get an insight into the not-so-talked-about but intense threats to MedTech.
Myriad Genetics' (MYGN) myChoice CDx test gets included in ASCO's latest recommendations for advanced ovarian cancer patients.
SALT LAKE CITY, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced today that the American Soc...
SALT LAKE CITY, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today anno...
Myriad Genetics (MYGN) sales in each of the operating segments plummet in the quarter owing to the full-quarter adverse impact of the pandemic.
But there were a few encouraging signs for the molecular-diagnostics company.
Myriad Genetics (MYGN) Q4 2020 Results - Earnings Call Transcript
Myriad (MYGN) delivered earnings and revenue surprises of 13.89% and -2.34%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
These are the stocks posting the largest moves after the bell Thursday.
Shares of Myriad Genetics (NASDAQ:MYGN) moved higher by 1.64% in after-market trading after the company reported Q4 results.
SALT LAKE CITY, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today anno...
SALT LAKE CITY, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, today ann...
On Thursday, August 13, Myriad Genetics (NASDAQ: MYGN) will report its last quarter's earnings.
About MYGN
Myriad Genetics, a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with delet... [Read more...]
| Industry Diagnostics & Research | IPO Date Oct 5, 1995 |
| CEO R. Bryan Riggsbee | Employees 2,700 |
| Stock Exchange NASDAQ | Ticker Symbol MYGN |
Analyst Forecasts
According to 9 analysts, the average rating for MYGN stock is "Hold." The 12-month stock price forecast is 26.00, which is a decrease of -15.99% from the latest price.